Tecfidera

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

dimetil fumarat

Available from:

Biogen Netherlands B.V.

ATC code:

L04AX07

INN (International Name):

dimethyl fumarate

Therapeutic group:

Imunosupresivi

Therapeutic area:

Multiple skleroza

Therapeutic indications:

Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

Product summary:

Revision: 28

Authorization status:

Pooblaščeni

Authorization date:

2014-01-30

Patient Information leaflet

                                28
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
EU/1/13/837/001
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Tecfidera 120 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
29
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
TOPLOTNO ZAVARJENO PAKIRANI PRETISNI OMOTI
1.
IME ZDRAVILA
Tecfidera 120 mg gastrorezistentne trde kapsule
dimetilfumarat
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Biogen Netherlands B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
zjutraj
zvečer
PON
TOR
SRE
ČET
PET
SOB
NED
_Sonce za simbol _
_Luna za simbol _
14 gastrorezistentnih trdih kapsul
PERORALNA UPORABA
Ena kapsula vsebuje 120 mg dimetilfumarata.
Pred uporabo preberite priloženo navodilo!
Zdravilo shranjujte nedosegljivo otrokom!
SHRANJUJTE PRI TEMPERATURI DO 30 ºC.
PRETISNE OMOTE SHRANJUJTE V ZUNANJI ŠKATLI
ZA ZAGOTOVITEV ZAŠČITE PRED SVETLOBO.
30
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
_ _
Tecfidera 120 mg
dimetilfumarat
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
31
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA
1.
IME ZDRAVILA
Tecfidera 240 mg gastrorezistentne trde kapsule
dimetilfumarat
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena gastrorezistentna trda kapsula vsebuje 240 mg dimetilfumarata.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
56 gastrorezistentnih trdih kapsul
168 gastrorezistentnih trdih kapsul
5.
POSTOPEK IN
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Tecfidera 120 mg gastrorezistentne trde kapsule
Tecfidera 240 mg gastrorezistentne trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Tecfidera 120 mg gastrorezistentne trde kapsule
Ena gastrorezistentna trda kapsula vsebuje 120 mg dimetilfumarata.
Tecfidera 240 mg gastrorezistentne trde kapsule
Ena gastrorezistentna trda kapsula vsebuje 240 mg dimetilfumarata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
gastrorezistentna trda kapsula
Tecfidera 120 mg gastrorezistentne trde kapsule
Zelene in bele gastrorezistentne trde kapsule, velikosti 0, z napisom
‘BG-12 120 mg’, ki vsebujejo
mikrotablete.
Tecfidera 240 mg gastrorezistentne trde kapsule
Zelene gastrorezistentne trde kapsule, velikosti 0, z napisom ‘BG-12
240 mg’, ki vsebujejo
mikrotablete.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Tecfidera je indicirano za zdravljenje odraslih in
pediatričnih bolnikov, starih 13 let ali več, z
recidivno-remitentno multiplo sklerozo (RRMS).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje naj se začne pod nadzorom zdravnika, ki ima izkušnje z
zdravljenjem multiple skleroze.
Odmerjanje
Začetni odmerek je 120 mg dvakrat na dan. Po 7 dneh je treba odmerek
zvišati na priporočeni
vzdrževalni odmerek 240 mg dvakrat na dan (glejte poglavje 4.4).
Če bolnik izpusti odmerek, ne sme vzeti dvojnega odmerka. Bolnik sme
vzeti izpuščeni odmerek le, če
so med odmerkoma minile 4 ure. V nasprotnem primeru mora bolnik
počakati do naslednjega
načrtovanega odmerka.
Začasno zmanjšanje odmerka na 120 mg dvakrat na dan lahko zmanjša
pojav vročinskih oblivov in
neželenih učinkov v prebavilih. V 1 mesecu je treba ponovno preiti
na priporočeni vzdrževalni
odmerek 240 mg dvakrat na dan.
3
Zdravilo Tecfidera se jemlje s hrano (glejte poglavje 5.2). Za
bolnike, ki imajo neželene učinke v
prebavilih ali vročinske oblive, lahko jemanje zdravila Tecfidera s
hrano izboljša prenašanje le tega
(glejte poglavja 4.4, 4
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 25-05-2022
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 25-05-2022
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 25-05-2022
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 25-05-2022
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 25-05-2022
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 25-05-2022
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 25-05-2022
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 25-05-2022
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 25-05-2022
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 25-05-2022
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 25-05-2022
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 25-05-2022
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 25-05-2022
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 25-05-2022
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 25-05-2022
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 25-05-2022
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 25-05-2022
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 25-05-2022
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 25-05-2022
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 25-05-2022
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 25-05-2022
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 25-05-2022

Search alerts related to this product

View documents history